

Surgical Science Q1 2024 - Soft streak continues

Redeye updates its estimates following Surgical Science's Q1 2024 report, which came in considerably below our estimates due to weak Educational Products sales. In contrast, Industry/OEM exceeded our estimates. Despite strong comparables, Educational Products' weakness surprised us. We lower our estimates for the segment and valuation.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Surgical Science Q1 2024 - Soft streak continues](#)